博碩士論文 105826014 詳細資訊




以作者查詢圖書館館藏 以作者查詢臺灣博碩士 以作者查詢全國書目 勘誤回報 、線上人數:22 、訪客IP:3.234.143.26
姓名 蕭升揚(Sheng-Yang Hsiao)  查詢紙本館藏   畢業系所 系統生物與生物資訊研究所
論文名稱 傳統中藥複方FY001W是三陰性乳腺癌新型的候選藥物
(Traditional Chinese Medicine FY001W as a novel candidate formula for triple negative breast cancer)
相關論文
★ 中草藥BP004誘導管腔A型乳腺癌細胞凋亡★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制
★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用
★ 泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色
★ BP016W-新型食道鱗狀上皮細胞癌候選藥物★ BP023W在頭頸癌中的細胞毒性與調控機制
★ 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經★ Solasodine,BP010W成份之一,抑制肺癌的遷移和侵襲能力
★ 蒙古黃耆對大腸癌影響並降低miR-29a的表現量之研究★ 利用生物資訊策略找出普濟方內加速傷口癒合的新配方
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   至系統瀏覽論文 (2023-1-28以後開放)
摘要(中) 乳腺癌是全世界女性最常見的癌症之一且有很多的亞型,而三陰性乳腺癌是乳腺癌中死亡率最高、治療後的預後效果最差的亞型。目前治療方式為放射治療、化學治療及乳房切除,這些治療的方式都會造成嚴重的副作用。中草藥的治療已經在中國有多年的記載並且文獻指出有較低的副作用及毒性。首先,我們選擇的古書為普濟方,此書為一本最完整且收入最多方劑的古書。從書中分析乳石門的複方並利用卡方檢定,篩選出升麻湯 (FY001W) 且可以有效地促使細胞的凋亡。而在傳統複方中有君、臣、佐、使的分類可以協助並了解複方中的核心藥材。利用統計方式分別找出4種加減方,並探討其加減方強弱相對於正常細胞及三陰性乳腺癌癌細胞的毒性的差異,從中找出FY003W可能為其核心藥材。利用流式細胞儀檢視出FY001W及其加減方對於三陰性乳腺癌細胞促使細胞走向凋亡,並且利用西方墨點法不同藥物不同濃度處理後觀察蛋白質的表現量,發現casepase-3、caspase-7、PARP隨著濃度上升表現量隨之降低,表示FY001W及其加減方能使細胞走向內部凋亡,而為了瞭解低濃度時細胞的存活我們查看了自噬作用的蛋白標誌ATG5、ATG16L1、ATG7、LC3A/B,發現隨著濃度上升其表現量一致地下降代表自噬作用的效果降低。未來我們會增加分析的背景資料並強化過去的資料,希望能更有效地找尋乳石門中的核心藥材。
摘要(英) Breast cancer is one of the most common cancers among women worldwide and has many subtypes. Triple-negative breast cancer is the subtype with the highest mortality in breast cancer and the worst prognosis after treatment. Current treatments are radiation therapy, chemotherapy, and mastectomy, all of which can cause serious side effects. The Chinese Medicine has documented for many years in China and the paper indicates that it has low side effects and toxicity. In our study, we find an ancient book, Pu Ji Fang, which is the most complete and comprehensive. We analyze formula of Ru Shi Men from Pu Ji Fang. Using the chi-square test to screen Sheng Ma Tang (FY001W) and effectively promote triple negative breast cancer cells apoptosis. However, there are consist of monarchs, ministers, Zuo, and ambassadors in the traditional formula. This classification assist and understand the core herbs in the formula. We hope to find the core herbs so using statistics to identify four derivatives. The FY001 and derivatives were treated in the triple negative breast cancer cells to induced apoptosis by flow cytometry, and the expression of protein were observed the different concentrations of different drugs by western blot. It was found that the protein expression casepase-3, caspase-7 and PARP decreased with the increase of concentration, indicating the cells underwent apoptosis through the intrinsic pathway. In order to realize the survival of cells at low concentrations, we investigate the autophagy markers ATG5, ATG16L1, ATG7, and LC3A/B. Finding the consistent decrease in the expression level as the concentration increased indicates that the effect of autophagy was reduced. In the future, we will enrich the background information to analyze and hoping to find the core herbs.
關鍵字(中) ★ 乳癌
★ MDA-MB-231
★ 凋亡
★ 自噬作用
★ 中草藥
★ 複方
★ 升麻湯
關鍵字(英) ★ breast cancer
★ MDA-MB-231
★ apoptosis
★ autophagy
★ TCM
★ formula
論文目次 中文摘要 I
Abstract II
致謝 III
圖目錄 VI
表目錄 VII
補充圖目錄 VIII
補充表目錄 IX
緒論 1
1-1 乳癌 1
1-2 乳腺癌的分群和靶向治療 2
1-3 治療及中藥的好處 3
1-4 普濟方 4
1-5 自噬作用及凋亡作用 5
1-6 研究目的 7
實驗方法與材料方法 8
2-1 細胞培養 8
2-2 普濟方資料整理 8
2-3 中草藥的配方 9
2-4 傳統中藥的萃取 10
2-5 細胞存活測定 11
2-6 藉由Flow檢測細胞的凋亡 11
2-7 蛋白質萃取 12
2-8 西方墨點法 12
2-9 晶片生物訊息分析 13
結果 14
3-1 生物資訊分析及小分子藥物 14
3-1-1 生物晶片 14
3-1-2 生物信息分析 16
3-1-3 nonoxynol-9 17
3-2 傳統中藥高通量藥物篩選系統 18
3-3 古書的探討及分析 20
3-3-1 普濟方的分析 20
3-3-2 藉由Alamar Blue研究FY001的毒性 29
3-3-3 藉由流式細胞儀凋亡的分析 30
3-4 FY001W加減方之療效 33
3-4-1 傳統中藥複方用藥配伍 33
3-4-2 FY001W加減方FY002及FY003誘導乳腺癌細胞凋亡 37
3-4-3 FY001W加減方FY004及FY005誘導乳腺癌細胞凋亡 41
3-4-4 FY001W及其加減方之藥效 42
3-5 FY001W及FY001W的加減方訊息途徑分析 44
討論 49
參考文獻 51
補充資料 53
參考文獻 1. American Cancer Society. Cancer Facts & Figures 2017;Avilable from:.
2. 衛生福利部. 106年國人死因統計結果.
3. Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 406(6797): p. 747-52.
4. Sorlie, T., et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 2001. 98(19): p. 10869-74.
5. Sorlie, T., et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 2003. 100(14): p. 8418-23.
6. Arvold, N.D., et al., Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol, 2011. 29(29): p. 3885-91.
7. Eroles, P., et al., Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev, 2012. 38(6): p. 698-707.
8. Cancello, G., et al., Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol, 2013. 24(3): p. 661-8.
9. Schnitt, S.J., Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol, 2010. 23 Suppl 2: p. S60-4.
10. Masuda, H., et al., Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res, 2013. 19(19): p. 5533-40.
11. Lehmann, B.D., et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 2011. 121(7): p. 2750-67.
12. Jamdade, V.S., et al., Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol, 2015. 172(17): p. 4228-37.
13. Dent, R., et al., Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007. 13(15 Pt 1): p. 4429-34.
14. Tao, J.J., K. Visvanathan, and A.C. Wolff, Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast, 2015. 24 Suppl 2: p. S149-53.
15. Chen, X.W., K.B. Sneed, and S.F. Zhou, Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications. Curr Med Chem, 2011. 18(21): p. 3190-210.
16. Patwardhan, B. and A.D. Vaidya, Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches. Indian J Exp Biol, 2010. 48(3): p. 220-7.
17. Ernst, E. and B.R. Cassileth, The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer, 1998. 83(4): p. 777-82.
18. Wen, Z., et al., Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PLoS One, 2011. 6(3): p. e18278.
19. Lam, W., et al., The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med, 2010. 2(45): p. 45ra59.
20. Kuai, L., et al., Sheng-ji Hua-yu formula promotes diabetic wound healing of re-epithelization via Activin/Follistatin regulation. BMC Complement Altern Med, 2018. 18(1): p. 32.
21. 維基百科,普濟方. 2009.
指導教授 蘇立仁(Li-Jen Su) 審核日期 2019-1-29
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題,請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407,或E-mail聯絡  - 隱私權政策聲明